This contract expires in 157 days (Nov 15, 2026).
PPD DEVELOPMENT LP - FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASURE
Key Details
Description
FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASURE
Context & Analysis
On Oct 23, 2025, Department of Health and Human Services obligated $724,461 to PPD DEVELOPMENT LP for fdabaa-24-00123, ref # fy24c1ep6, cardiovascular-kidney-metabolic (ckm) syndrome patient-reported outcome (pro) burden measure. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: competed under sap with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in WILMINGTON, NC. The contract is scheduled through Nov 15, 2026 — approximately 5 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.